Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518386-95-02

Acronym

CABinMET

Enrollment

Registered

2025-02-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small-cell lung cancer

Brief summary

Response Rate (RR) (complete + partial responses) of Cabozantinib in NSCLC patients with MET amplification or MET exon 14 skipping mutation pre-treated or not with MET inhibitors.

Detailed description

- Progression free survival (PFS) - Overall survival (OS) - Disease Control Rate (DCR: stable disease + partial response + complete response) - Exploratory biomarkers on blood and tissue samples (for each patient enrolled in the study optionally a tissue sample could be provided at disease progression)

Interventions

DRUGCABOMETYX 20 mg film-coated tablets

DRUGCABOMETYX 60 mg film-coated tablets

DRUGCABOMETYX 40 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Response Rate (RR) (complete + partial responses) of Cabozantinib in NSCLC patients with MET amplification or MET exon 14 skipping mutation pre-treated or not with MET inhibitors.	—

Secondary

Measure	Time frame
- Progression free survival (PFS) - Overall survival (OS) - Disease Control Rate (DCR: stable disease + partial response + complete response) - Exploratory biomarkers on blood and tissue samples (for each patient enrolled in the study optionally a tissue sample could be provided at disease progression)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026